Longer spondyloarthritis duration tied to increased risk of developing hypertension

  • Derakhshan MH & al.
  • J Rheumatol
  • 15 Jan 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.


  • Hypertension is associated with increased spondyloarthritis (SpA) disease duration and delay in SpA diagnosis.
  •  This association is stronger in patients with axial disease than in those with peripheral disease.

Why this matters

  • Regular blood pressure measurement would help physicians better manage patients with SpA, particularly those with longer disease duration.

Study design

  • Analysis of data from the ASAS-COMOSPA (Assessment of Spondylo-arthritis international Society–COMOrbidities in Spondylo-Arthritis) study (n=3923; median SpA disease duration, 5.1 years; interquartile range, 1.3-11.8 years).
  • Associations between SpA disease duration and CV-related conditions were evaluated using univariable and multivariable logistic regression analyses.
  • Funding: COMOSPA study was supported by AbbVie, Pfizer and UCB.

Key results

  • The main CV-related conditions assessed were hypertension (22.4%), dyslipidaemia (16.6%), ischaemic heart disease (2.6%), stroke (1.3%) and diabetes mellitus (5.5%).
  • Odds of having a diagnosis of hypertension increased by 13% per each 5-year increase in the duration of SpA (OR, 1.13; 95% CI, 1.07-1.19; P<.001>
  • A weak but marginally significant association was observed between hypertension and delay in SpA diagnosis (OR, 1.01; 95% CI, 1.00-1.02; P=.033).
  • Factors associated with hypertension were age, male sex, current body mass index, ever use of steroid therapy and synthetic disease-modifying antirheumatic drug therapy, but not ever use of nonsteroidal anti-inflammatory drugs.
  • Strongest association of hypertension and disease duration was seen in patients with the axial-only SpA phenotype (OR, 1.20; 95% CI, 1.05-1.37) but not in those with peripheral-only SpA (OR, 0.90; 95% CI, 0.76-1.07).
  • Other CV-related conditions showed no association with SpA disease duration.


  • Self-reported data may incur recall bias.